Aluminum hydroxide suspension (Alum)

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network

Conditions

HIVHIV Infections

Phase 1

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

WithdrawnNCT06267872

National Institute of Allergy and Infectious Diseases (NIAID)HIV

Start: 2024-10-07End: 2026-09-12Updated: 2025-03-26

Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected

Not yet recruitingNCT06613789

HIV Vaccine Trials NetworkHIV Infections

Start: 2026-07-13End: 2027-06-03Target: 22Updated: 2025-12-09